S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
In a challenging market environment, Neuraxis Inc. (NRXS) stock has touched a 52-week low, falling to $1.98. The small-cap biopharmaceutical company, valued at $15.51 million and specializing in developing treatments for central nervous system disorders, has seen its shares struggle significantly over the past year. According to InvestingPro data, despite maintaining impressive gross profit margins of 86.5%, the company is currently unprofitable and burning through cash rapidly. Investors have witnessed a notable decline in the value of their holdings, with Neuraxis stock experiencing a 1-year change of -32.58%. This downturn reflects broader market trends and investor sentiment, as the company navigates through a complex healthcare landscape and competitive pressures. The current price level marks the lowest point for Neuraxis stock in the last year, underlining the need for strategic initiatives to bolster investor confidence and company growth. InvestingPro analysis suggests the stock is currently fairly valued, with analysts setting a target price of $4.75. Discover more insights and 6 additional ProTips for NRXS in the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Neuraxis Inc. reported a strong performance in the fourth quarter of 2024, with revenue increasing by 43% year-over-year to $761,000. The company’s full-year revenue reached $2.7 million, reflecting a 9% increase from the previous year. Neuraxis also improved its net loss by 73% in Q4 compared to the same period last year, with an operating loss of $1.5 million. Notably, the company has expanded its FDA approvals and market reach, a development that could potentially drive future growth. Analysts have noted that Neuraxis is targeting cash flow breakeven, with expectations for revenue acceleration in 2025 and 2026, driven by the introduction of a second-generation IVStim device. Additionally, Neuraxis received a Category One CPT code, effective January 2026, which is expected to streamline billing and reimbursement processes. The company is also focusing on expanding insurance coverage, which has increased from 4 million to 51 million covered lives. These recent developments suggest that Neuraxis is positioning itself for significant growth in the coming years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.